Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, announces today that Nikolas Sofronis and Russell Barry Gibbs have resigned as directors of the Company with effect from 31 December 2008..
Commenting on the resignations, Steve Harris, Chairman of Cyprotex said:
"Both Nikolas and Russell have made significant contributions to the development of Cyprotex over the years for which we are extremely grateful. I thank them on behalf of the Company and wish them well in the future. Cyprotex is actively seeking candidates for the Board vacancies created by their resignations."
For further information:
Dr Anthony Baxter, CEO
Tel: +44 (0)1625 505 100
Nomura Code Securities Limited:
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
Tel: +44 (0)20 743 6670